Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis
Dec 31, 2015
Treatment Advances in Achieving Remission in Mild to
Moderate Ulcerative Colitis
Goals of Therapy for Patients With UC
Sequential Therapies for UC
Oral 5-ASA Formulations: Sites of Delivery
Conventional Corticosteroids in UC
Corticosteroids: Dependency—Short- and Long-term Efficacy
CORE I and II: Budesonide MMX Primary End Point: Combined Clinical and Endoscopic
Remission
Azathioprine vs 5-ASA for Corticosteroid-Dependent, Active
UC
Anti-TNF Therapies for Moderate to Severe Disease
Treatment Algorithm to Maximize Remission and Minimize
Corticosteroid Dependence in UC
Patient Case
Mesalamine Safety
Patient Case (cont)
Pooled Safety Data: Adverse Effects of Budesonide MMX in Patients With Active UC
Anti-TNF Agents: Adverse Events
Minimizing Toxicity for Anti-TNF Therapy
Summary: Safety
Effect on Bone Density
Monitoring the Patient Receiving Budesonide MMX
Summary: Safety of Agents Used to Induce Remission in Mild to
Moderate UC
Abbreviations
References
References (cont)
References (cont)